Endogenous PTH Deficiency Impairs Fracture Healing and Impedes the Fracture-Healing Efficacy of Exogenous PTH(1-34) by Ren, Yongxin et al.
Endogenous PTH Deficiency Impairs Fracture Healing












1Department of Orthopaedics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China, 2Department of Orthopaedics, The Liyang People’s Hospital,
Changzhou, China, 3The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, China,
4Department of Medicine, McGill University, Montreal, Canada
Abstract
Background: Although the capacity of exogenous PTH1-34 to enhance the rate of bone repair is well established in animal
models, our understanding of the mechanism(s) whereby PTH induces an anabolic response during skeletal repair remains
limited. Furthermore it is unknown whether endogenous PTH is required for fracture healing and how the absence of
endogenous PTH would influence the fracture-healing capacity of exogenous PTH.
Methodology/Principal Findings: Closed mid-diaphyseal femur fractures were created and stabilized with an
intramedullary pin in 8-week-old wild-type and Pth null (Pth
2/2) mice. Mice received daily injections of vehicle or of
PTH1-34 (80 mg/kg) for 1–4 weeks post-fracture, and callus tissue properties were analyzed at 1, 2 and 4 weeks post-fracture.
Cartilaginous callus areas were reduced at 1 week post-fracture, but were increased at 2 weeks post-fracture in vehicle-
treated and PTH-treated Pth
2/2 mice compared to vehicle-treated and PTH-treated wild-type mice respectively. The
mineralized callus areas, bony callus areas, osteoblast number and activity, osteoclast number and surface in callus tissues
were all reduced in vehicle-treated and PTH-treated Pth
2/2 mice compared to vehicle-treated and PTH-treated wild-type
mice, but were increased in PTH-treated wild-type and Pth
2/2 mice compared to vehicle-treated wild-type and Pth
2/2 mice.
Conclusions/Significance: Absence of endogenous PTH1-84 impedes bone fracture healing. Exogenous PTH1-34 can act in
the absence of endogenous PTH but callus formation, including accelerated endochondral bone formation and callus
remodeling as well as mechanical strength of the bone are greater when endogenous PTH is present. Results of this study
suggest a complementary role for endogenous PTH1-84 and exogenous PTH1-34 in accelerating fracture healing.
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Introduction
The major form of bioactive parathyroid hormone (PTH)
secreted by the parathyroid glands is an 84-amino acid peptide. In
response to a hypocalcemic stimulus increased endogenous PTH
release can raise extracellular calcium levels by indirectly
enhancing gastrointestinal calcium absorption through its action
on stimulating 1,25 dihydroxyvitamin D (1,25(OH)2D) production,
and by directly enhancing renal calcium reabsorption and
osteoclastic bone resorption, thereby releasing calcium from the
skeleton. Although endogenous PTH1-84, is classically believed to
function as a bone resorbing hormone to maintain calcium
homeostasis, endogenous PTH also has a critical role to play in the
development and maintenance of trabecular bone mass, particu-
larly in the fetus and the neonate. We previous demonstrated this
skeletal anabolic role for endogenous PTH1-84 using a genetic
approach [1,2]. We found that osteoblast number and trabecular
bone volume were reduced in newborn [1] and 2-week-old [2]
PTH null mice. We have previously reported a mouse model
deficient in 1,25(OH)2D by targeted ablation of the 25-
hydroxyvitamin D-1a-hydroxylase enzyme (1a(OH)ase
2/2) [3].
After weaning, mice fed a diet of regular mouse chow developed
hyperparathyroidism, and exhibited the retarded growth and
skeletal abnormalities characteristic of rickets. Bone volume and
osteoblast numbers were increased in the 1a(OH)ase
2/2 animals
with secondary hyperparathyroidism [3]. These increases most
likely also reflect ‘‘anabolic’’ activity of endogenous PTH1-84.
Numerous studies have demonstrated that exogenous PTH1-84,
and exogenous PTH1-34 (a synthetic polypeptide that comprises
the bioactive 1–34 amino acid fragment of PTH), when
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bone mass [4,5] and both PTH1-84 and PTH1-34, either of which
can bind to the type I PTH/PTHrP receptor (PTHR1), are in
clinical use for the treatment of osteoporosis. When injected
subcutaneously once a day in osteoporotic patients, it stimulates
cancellous bone formation, increases bone mineral density (BMD),
and reduces the risk of fracture [6]. The capacity of daily injections
of exogenous PTH1-34 [7,8,9,10,11] or exogenous PTH1-84 [12]
to enhance fracture healing has been examined in several rodent
models. All showed significant increases in the mechanical
properties of the calluses, rates of callus formation, and callus
tissue volume [7,8,9,11]. In other studies using models of impaired
bone metabolism, PTH analogs or PTH were shown to reverse the
inhibition of bone healing observed in aged and ovariectomized
rats [10,12]. Although the ability of exogenous PTH to enhance
the rate of bone repair is thus well established in animal models, it
is unknown whether endogenous PTH1-84 is required for fracture
healing.
To assess whether endogenous PTH1-84 deficiency impairs
fracture healing and to determine what the effect of the absence of
endogenous PTH1-84 might be on the capacity of exogenous
PTH1-34 to accelerate fracture healing, closed mid-diaphyseal
femur fractures were created and stabilized with an intramedullary
pin in 8-week-old wild-type and Pth-null (Pth
2/2) mice. Mice
received daily injections of vehicle or of PTH1-34 (80 mg/kg) for
1–4 weeks post-fracture, and callus tissue properties was analyzed
at 1, 2 and 4 weeks post-fracture by radiography, micro-CT,
histology, histochemistry and immunohistochemistry. RNA and
proteins were isolated from callus tissues and bone formation-
related gene and protein expression levels were evaluated by real-
time RT-PCR and Western blots, respectively.
Materials and Methods
Derivation of Pth null mice
The derivation of the parental strain of Pth
2/2 mice by
homologous recombination in embryonic stem cells and genotyp-
ing of mice were previously described by Miao et al [1,13]. Briefly,
a neomycin resistance gene was inserted into exon III of the mouse
Pth gene replacing the entire mature Pth coding sequence. Lack of
PTH expression was confirmed by immunostaining of parathyroid
gland sections [1]. Eight-week-old wild-type and Pth
2/2 mice were
used in this study.
Creation of femur fractures and administration of PTH1-
34
A standardized mid-diaphyseal fracture was induced in 36 8-
week-old wild-type mice and 36 8-week-old Pth
2/2 mice as
described previously [14]. Briefly, after sedation of the animals
with isoflurane (ForeneH) and intraperitoneal anesthesia with a
mixture of ketamine hydrochloride (100 mg/ml; 80 mg/kg body
weight) and xylazin 2% (12 mg/kg body weight), the right hind leg
was shaved and disinfected. An intramedullary pin (Ø=0.5 mm)
was introduced into the femoral canal through a medial
parapatellar incision and arthrotomy of the knee. After closing
the wound, a mid-diaphyseal fracture was produced by using a
falling weight of 300 g over a threepoint bending mechanism. In
all groups, the drop height of the weight was 15 cm. The fracture
was radiographically documented. In all cases, a straight mid-
diaphyseal fracture was induced. At the time of fracture, wild type
and Pth
2/2 mice received daily injections of vehicle or of PTH1-
34 (80 mg/kg) subcutaneously for 1–4 weeks. The use of animals in
this study was approved by the Institutional Animal Care and Use
Committee of Nanjing Medical University (Approval ID 2008-
00318).
Skeletal radiography
Femurs were removed and dissected free of soft tissue from 6
mice of each group. Contact radiographs were taken using a
Faxitron model 805 radiographic inspection system (Faxitron
Contact, Faxitron, Germany) (22 kV voltage and 4 min exposure
time). X-Omat TL film (Eastman Kodak Co., Rochester, NY,
USA) was used and processed routinely.
Micro-computed tomography
After radiography examination, femurs were analyzed by
micro-CT with a SkyScan 1072 scanner and associated analysis
software (SkyScan, Antwerp, Belgium) as described [2]. Briefly,
image acquisition was performed at 100 kV and 98 mA with a
0.98 rotation between frames. During scanning, the samples were
enclosed in tightly fitting plastic wrap to prevent movement and
dehydration. Thresholding was applied to the images to segment
the bone from the background. Two-dimensional images were
used to generate three-dimensional renderings using the 3D
Creator software supplied with the instrument. The resolution of
the micro-CT images is 18.2 mm. A volume of interest for
quantitative analysis was defined, extending from the proximal to
the distal end of the callus region. For each 3D image, total bone
volume was calculated, including both the cortical bone and the
surrounding new bone formation. Following manual segmenta-
tion, a second evaluation was then performed to calculate bone
volume of the cortical bone alone. Finally, the calcified callus
volume was determined by subtracting the cortical bone volume
from the total volume.
Biomechanical testing
Four weeks after fracture, femurs of 6 vehicle-treated wild-type
and Pth
2/2 mice and 6 PTH-treated wild-type and Pth
2/2 mice
were rehydrated at room temperature in phosphate buffered saline
(PBS) and their biomechanical properties were assessed by a three-
point bending test. Strength tests were performed at the right
femur midshaft with a displacement rate of 10 mm/minute (span
length, 10 mm) using a mechanical testing machine (model 5865;
Instron, Norwood, MA). Whole-bone mechanical properties,
including maximum load, maximum stress and energy-to-failure,
were determined using load-deflection diagrams. Maximum stress
was calculated as s = y F L/4 I, where s = maximum stress (Pa
(N/m
2), N/mm
2, psi), y = Perpendicular distance from to neutral
axis (m, mm, in), F = load (N, lb), L = length between two





Proteins were extracted from 6 callus tissues of each group and
quantitated using a kit (Bio-Rad, Mississauga, Ontario, Canada).
Thirty-microgram protein samples were fractionated by SDS-
PAGE and transferred to nitrocellulose membranes. Immunoblot-
ting was carried out as described [15] using antibodies against
insulin-like growth factor 1 (IGF-1) (Santa Cruz, CA, USA) and
core binding factor alpha1 (Cbfa1) (Santa Cruz, CA, USA) and b-
tubulin (Santa Cruz, CA, USA) was used as a loading control.
Bands were visualized using enhanced chemiluminescence (Amer-
sham, Aylesbury, UK).
Quantitative real-time RT-PCR
RNA was isolated from 6 callus tissues of each group, using
Trizol reagent (Invitrogen) according to the manufacturer’s
PTH Accelerates Fracture Healing
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SuperScript First-Strand Synthesis System (Invitrogen) as previ-
ously described [2]. To determine the number of cDNA molecules
in the reverse transcribed samples, real-time PCR analyses were
performed using the LightCycler system (Roche, Indianapolis, IN).
PCR was performed using 2 ml LightCycler DNA Master SYBR
Green I (Roche), 0.25 mM of each 59 and 39 primer, and 2 ml
samples or H2O to a final volume of 20 ml. The MgCl2
concentration was adjusted to 3 mM. Samples were denatured
at 95uC for 10 sec, with a temperature transition rate of 20uC per
sec. Amplification and fluorescence determination were carried
out in four steps: denaturation at 95uC for 10 sec, with a
temperature transition rate of 20uC/sec; annealing for 5 sec, with
a temperature transition rate of 8uC/sec; extension at 72uC for
20 sec, with a temperature transition rate of 4uC/sec; and
detection of SYBR Green fluorescence, which reflects the amount
of double-stranded DNA, at 86uC for 3 sec. The amplification
cycle number was 35. To discriminate specific from nonspecific
cDNA products, a melting curve was obtained at the end of each
run. Products were denatured at 95uC for 3 sec, and the
temperature was then decreased to 58uC for 15 sec and raised
slowly from 58 to 95uC using a temperature transition rate of
0.1uC/sec. To determine the number of copies of the targeted
DNA in the samples, purified PCR fragments of known
concentrations were serially diluted and served as external
standards that were measured in each experiment. Data were
normalized with GAPDH levels in the samples. The primer
sequences used for the real-time PCR were the same as described
previously [16].
Histology
Femurs were removed from 6 mice of each group and fixed in
PLP fixative (2% paraformaldehyde containing 0.075 M lysine
and 0.01 M sodium periodate) overnight at 4uC and processed
histologically as described [17]. Femurs were decalcified in
ethylene-diamine tetraacetic acid (EDTA)-glycerol solution for
5–7 days at 4uC. Decalcified femurs were dehydrated and
embedded in paraffin, after which 5 mm sections were cut on a
rotary microtome. The sections were stained with hematoxylin
and eosin (HE) or histochemically for total collagen and alkaline
phosphatase (ALP) activity and tartrate-resistant acid phosphatase
(TRAP) or immunohistochemical staining as described below.
Histochemical staining for collagen, ALP and TRAP
Total collagen was detected in paraffin-embedded sections using
a modification of the method of Lopez-De Leon and Rojkind as
described previously [18]. Dewaxed sections were exposed to 1%
sirius red in saturated picric acid for 1 h. After washing with
distilled water, the sections were counterstained with hematoxylin
and mounted with Biomount medium.
Enzyme histochemistry for ALP activity was performed as
described in paraffin sections [19]. Briefly, following preincubation
overnight in 1% magnesium chloride in 100 mM Tris–maleate
buffer (pH 9.2), de-waxed sections were incubated for 2 h at room
temperature in a 100 mM Tris–maleate buffer containing
naphthol AS-MX phosphate (0.2 mg/ml, Sigma) dissolved in
ethylene glycol monomethyl ether (Sigma-Aldrich, St Louis, MO,
USA) as substrate and fast red TR (0.4 mg/ml, Sigma) as a stain
for the reaction product. After washing with distilled water, the
sections were counterstained with Vector methyl green nuclear
counterstain (Vector Laboratories, Burlingame, CA, USA) and
mounted with Kaiser’s glycerol jelly.
Enzyme histochemistry for TRAP was performed on paraffin
sections using a modification of a previously described protocol
[20]. Dewaxed sections were preincubated for 20 min in buffer
containing 50 mM sodium acetate and 40 mM sodium tartrate at
pH 5.0. Sections were then incubated for 15 min at room
temperature in the same buffer containing 2.5 mg/ml naphthol
AS-MX phosphate (Sigma) in dimethylformamide as substrate and
0.5 mg/ml fast garnet GBC (Sigma) as a color indicator for the
reaction product. After washing with distilled water, the sections
were counterstained with methyl green and mounted in Kaiser’s
glycerol jelly.
Immunohistochemical staining
Immunohistochemical staining for type I collagen was per-
formed on paraffin sections using the avidin-biotin-peroxidase
complex technique with affinity-purified goat anti-human type I
collagen antibody (Southern Biotechnology Associates, Birming-
ham, AL, USA). Briefly, dewaxed and rehydrated paraffin-
embedded sections were incubated with methanol-hydrogen
peroxide (1:10) to block endogenous peroxidase activity and then
washed in Tris-buffered saline (pH 7.6). The slides were then
incubated with the primary antibody overnight at room
temperature. After rinsing with Tris-buffered saline for 15 min,
tissues were incubated with biotinylated secondary antibody
(Sigma). Sections were then washed and incubated with the
Vectastain Elite ABC reagent (Vector Laboratories) for 45 min.
After washing, brown pigmentation was likewise produced using
3,3-diaminobenzidine (2.5 mg/ml). After washing with distilled
water, the sections were counterstained with Mayer’s hematoxylin,
dehydrated in graded ethanol and xylene and mounted with
Biomount medium.
Computer-assisted image analysis
After HE staining, or histochemical or immunohistochemical
staining of sections from six mice of each genotype, images of fields
were photographed with a Sony digital camera. Images of
micrographs from single sections were digitally recorded using a
rectangular template, and recordings were processed and analyzed
using Northern Eclipse image analysis software as described
[2,17]. All measurements were performed in a blinded fashion.
The region of interest (ROI) was defined as the area of the callus
on both sides of the medullary canal excluding all cortical bone.
This ROI was outlined manually for each specimen using the
software.
Statistical Analysis
Data from image analysis are presented as mean 6 SEM.
Statistical comparisons were made using a two-way ANOVA, with
P,0.05 being considered significant.
Results
Effects of endogenous PTH deficiency and of exogenous
PTH on bone fracture healing
Effects of endogenous PTH1-84 deficiency and exogenous
PTH1-34 on bone fracture healing were examined at 2 and 4
weeks post-fracture in vehicle-treated wild-type and Pth
2/2 mice
and in PTH-treated wild-type and Pth
2/2 mice by radiography
(Fig. 1A) and micro-CT (Figs. 1B and C). By radiography (Fig. 1A),
the front view (Fig. 1B) and longitudinal sections (Fig. 1C) of
micro-CT 3-dimensional reconstructions and quantitative analysis
(Figs. 1D and E) demonstrated that the size of callus and the
calcified callus volume at 2 weeks post-fracture were reduced in
vehicle-treated and PTH-treated Pth
2/2 mice compared to
vehicle-treated and PTH-treated wild-type mice, respectively,
and were increased in PTH-treated wild-type and Pth
2/2 mice
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mice respectively. In addition, the fracture repairs at 4 weeks post-
fracture were poor in Pth
2/2 mice compared to wild-type mice,
and were improved significantly in PTH1-34-treated wild-type
and Pth
2/2 mice. However, the best fracture repairs were
observed in the PTH-treated wild-type mice.
Figure 1. Effects of endogenous PTH deficiency and exogenous PTH on bone fracture healing and mechanical properties of fractured
femurs. (A) Representative radiographs offemurs fromvehicle-treatedwild-type (V-WT) andvehicle-treatedPth
2/2 (V-KO) mice and PTH-treated wild-type
(PTH-WT) and PTH-treated Pth
2/2 (PTH-KO) mice at 2 weeks (2W) and 4 weeks (4W) post-fracture. Representative (B) frontal views and (C) longitudinal
sections of micro-CT 3-dimensional reconstructed calluses from V-WT and V-KO mice and PTH-WT and PTH-KO mice at 2 week and 4 weeks post-fracture.
The quantitative analysis for calcified callus volume at (D) 2 weeks (2W) and (E) 4 weeks (4W) post-fracture. (F) Maximum load, (G) maximum stress and (H)
energy-to failure were assessed by three-point bending in femurs from 4 weeks post-fracture in vehicle-treated wild-type (WT) and Pth
2/2 mice (KO) and
PTH-treated wild-type and Pth
2/2 mice. Eachvalueis the mean 6 SEM of determinations in 6 animals from each group. *, P,0.05; **, P,0.01; ***, P,0.001
compared with WT mice at the same group. #,P ,0.05; ##,P ,0.01; ###,P ,0.001 compared with genotype-matched V-treated mice.
doi:10.1371/journal.pone.0023060.g001
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PTH on mechanical properties of fractured femurs at 4
weeks post-fracture
To assess effects of endogenous PTH deficiency and of
exogenous PTH on mechanical properties of fractured femurs,
biomechanical properties were examined by three-point bending
in femurs 4 weeks after fracture in vehicle-treated wild-type and
Pth
2/2 mice and PTH-treated wild-type and Pth
2/2 mice. Results
revealed that maximum load (Fig. 1F), maximum stress (Fig. 1G)
and energy-to failure (Fig. 1H) were all reduced in vehicle-treated
and PTH-treated Pth
2/2 mice compared to vehicle-treated and
PTH-treated wild-type mice, respectively, and were increased in
PTH-treated wild-type and Pth
2/2 mice compared to vehicle-
treated wild-type and Pth
2/2 mice, respectively.
Effects of endogenous PTH deficiency and of exogenous
PTH on cartilaginous callus formation and on the
transformation into bony callus
To determine whether endogenous PTH deficiency and
exogenous PTH affect cartilaginous callus formation and its
transformation into bony callus, callus tissues from vehicle-treated
wild-type and Pth
2/2 mice and PTH-treated wild-type and Pth
2/2
mice were analyzed at 1 and 2 weeks post-fracture by histology
and computer-assisted image analysis. Results showed that at 1
week post-fracture, total callus areas, cartilaginous callus areas and
bony callus areas were reduced in vehicle-treated and PTH-
treated Pth
2/2 mice compared to vehicle-treated and PTH-treated
wild-type mice respectively, but were increased in both PTH-
treated wild-type and Pth
2/2 mice compared to vehicle-treated
wild-type and Pth
2/2 mice respectively (Figs. 2A, C–E). At 2 weeks
post-fracture, total callus areas and bony callus areas were reduced
in vehicle-treated and PTH-treated Pth
2/2 mice compared to
vehicle-treated and PTH-treated wild-type mice respectively, but
were increased in both PTH-treated wild-type and Pth
2/2 mice
compared to vehicle-treated wild-type and Pth
2/2 mice respec-
tively (Figs. 2B, F and H). In contrast, at 2 weeks post-fracture,
remnant cartilaginous callus areas were increased in vehicle-
treated and PTH-treated Pth
2/2 mice compared to vehicle-treated
and PTH-treated wild-type mice respectively, and were reduced in
PTH-treated wild-type and Pth
2/2 mice compared to vehicle-
treated wild-type and Pth
2/2 mice, respectively (Figs. 2B and G).
The percentage of increased total callus and bony callus in
response to PTH was greater at 1 and 2 weeks post-fracture in
Pth
2/2 mice than in wild type mice (Figs. 2I and K). The
percentage of increased cartilaginous callus in response to PTH
was greater at 1 week post-fracture in Pth
2/2 mice than in wild
type mice, whereas the percentage of reduced cartilaginous callus
in response to PTH was less at 2 week post-fracture in Pth
2/2 mice
than in wild type mice (Fig. 2J).
Effects of endogenous PTH deficiency and of exogenous
PTH on the expression of osteoblastic bone formation
related genes and proteins in callus tissues at 1 and 2
weeks post-fracture
To determine whether the alterations of the bony callus areas
were associated with the regulation of the expression of
osteoblastic bone formation related genes and proteins in callus
tissues, mRNA and proteins were isolated from callus extracts
from vehicle-treated wild-type and Pth
2/2 mice and PTH-treated
wild-type and Pth
2/2 mice. The expression of ALP and type I
collagen genes and the expression of Cbfa1 and IGF-1 proteins
were examined at 1 and 2 weeks post-fracture by real-time RT–
PCR and Western blots, respectively. At 1 and 2 weeks post-
fracture, the mRNA levels of ALP and type I collagen, and the
protein levels of Cbfa1 and IGF-1 were reduced in vehicle-treated
and PTH-treated Pth
2/2 mice compared to vehicle-treated and
PTH-treated wild-type mice, respectively, and were increased in
PTH-treated wild-type and Pth
2/2 mice compared to vehicle-
treated wild-type and PTH-treated Pth
2/2 mice, respectively
(Fig. 3).
Effects of endogenous PTH deficiency and of exogenous
PTH on osteoblastic bone formation in calluses at 4
weeks post-fracture
To determine effects of endogenous PTH deficiency and
exogenous PTH on osteoblastic bone formation in calluses, bony
callus volume and osteoblast number and activity were examined
at 4 weeks post-fracture by histology, histochemistry and
immunohistochemistry. At 4 weeks post-fracture, total collagen
positive bony callus areas, osteoblast number, ALP positive areas
and type I collagen immunopositive areas were all reduced in
vehicle-treated and PTH-treated Pth
2/2 mice compared to
vehicle-treated and PTH-treated wild-type mice, respectively,
and were increased in PTH-treated wild-type and Pth
2/2 mice
compared to vehicle-treated wild-type and Pth
2/2 mice, respec-
tively (Fig. 4).
Effects of endogenous PTH deficiency and of exogenous
PTH on osteoclastic bone resorption in calluses at 2 and
4 weeks post-fracture
To determine whether endogenous PTH deficiency and
exogenous PTH affect osteoclastic bone resorption during bone
fracture healing, osteoclastic bone resorption was examined in
callus tissues at 2 and 4 weeks post-fracture by histochemical
staining and computer-assist image analysis. Results revealed that
at 2 and 4 weeks post-fracture, the TRAP positive osteoclast
number and surface were reduced in vehicle-treated and PTH-
treated Pth
2/2 mice compared to vehicle-treated and PTH-treated
wild-type mice respectively,but were increased in PTH-treated
wild-type and Pth
2/2 mice compared to vehicle-treated wild-type
and Pth
2/2 mice respectively (Fig. 5).
Discussion
Our study demonstrates that deficiency of endogenous PTH
impairs the fracture repair process, by reducing cartilaginous and
bony callus formation with down-regulation of osteoblastic gene
and protein expression, and reduction of endochondral bone
formation, osteoblastic bone formation and osteoclastic bone
resorption. These results indicate that endogenous PTH plays an
important role in fracture healing. These findings are consistent
with a previous study that reported that in parathyroidectomized
rats with decreased serum PTH, fracture healing was impaired
due to delay of both chondroclasts at the phase of endochondral
ossification and secondary remodeling of primary cancellous bone
[21]. We previously reported that Pth
2/2 mice which have absent
endogenous PTH, have decreased osteoblast and osteoclast
numbers and diminished trabecular bone volume at birth,
demonstrating that PTH is essential for fetal trabecular bone
formation [1]. We also observed similar phenotypic alterations in
2-week-old Pth
2/2 mice in that trabecular bone formation and
trabecular bone volume were reduced when compared with wild-
type littermates [2]. Consequently endogenous PTH appears to
play an important role be in the regulation of normal trabecular
bone formation. Pth
2/2 mice also displayed reduced mineraliza-
tion and diminished vascular invasion at the chondro-osseous
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for endogenous PTH in endochondral bone formation during
normal development may therefore be recapitulated in the process
of endochondral bone formation occurring during the fracture
healing process.
Several animal studies have documented that exogenous PTH,
either PTH1-34 or PTH1-84, enhances fracture healing and is
able to stimulate hard-callus formation and increase the strength of
the fracture site. Our results also demonstrated that PTH1-34
treatment of wild type mice enlarged the cartilaginous callus and
accelerated cartilaginous callus transformation into bony callus.
Upregulation of IGF-1 was observed in our studies in response to
exogenous PTH treatment. It has previously been suggested that
IGF-I mediates the proliferative effect of PTH on mesenchymal
cells, which may then differentiate into cells of the chondrogenic
lineage, thereby contributing to the increased size of the
cartilaginous callus upon PTH1–34 treatment [22]. Our studies
are consistent with those observations. Studies have also suggested
direct effects of PTH on chondrocyte proliferation and differen-
tiation [22,23]. We previously reported that the proliferation and
apoptosis of chondrocytes were not altered significantly in
newborn and 2-week-old Pth
2/2 mice which lack endogenous
PTH. Indeed PTH, which is not expressed in chondrocytes or
cartilaginous callus, and which must access PTHR1 via the blood
stream (whether it is of endogenous or exogenous origin), is
unlikely to directly interact with chondrocytes in the avascular
cartilaginous growth plate [1,2]. It is however possible that
chondrocyte proliferation and differentiation are influenced
indirectly by increases in extracellular calcium observed after
exogenous PTH1-34 administration. The increase in bony callous
formation was accompanied by up-regulation of Cbfa1 protein
levels and by up-regulation of ALP and type I collagen mRNA
levels and at 1 and 2 weeks post-fracture, by increased bony callus
volume, osteoblast number, ALP and type I collagen positive areas
at 4 weeks post-fracture, and by increased osteoclast number and
surface at 2 and 4 weeks post-fracture. Exogenous PTH1-34
therefore not only stimulated bony callus formation by enhancing
osteoblastic bone formation but also accelerated bony callus
remodeling by stimulating osteoclastic bone resorption. Taken
together these data indicate that exogenous PTH 1–34 promotes
Figure 3. Effects of endogenous PTH deficiency and exogenous PTH on the expression of osteoblastic bone formation related
genes and proteins in callus tissues at 1 and 2 weeks post-fracture. Real-time RT–PCR was performed on callus extracts from V-WT and V-KO
mice and PTH-WT and PTH-KO mice at 1 week and 2 weeks post-fracture for gene expression of (A, B) ALP and (C, D) type I collagen (Col I). Messenger
RNA expression was calculated as a ratio relative to the GAPDH mRNA level and expressed relative to levels of V-WT mice. (E) Western blots for
protein expression of Cbfa1, and insulin-like growth factor-1 (IGF-1), of callus extracts from V-WT and V-KO mice and PTH-WT and PTH-KO mice at 1
week and 2 weeks post-fracture. b-tubulin was used as loading control for Western blots. (F, G) Cbfa1 and (H, I) IGF-1 protein levels relative to b-
tubulin protein level were assessed by densitometric analysis and expressed relative to levels of V-WT mice. Each value is the mean 6 SEM of
determinations in 6 animals from each group. *, P,0.05; **, P,0.01; ***, P,0.001 compared with WT mice of the same group. #,P ,0.05;
##,P ,0.01; ###,P ,0.001 compared with genotype-matched V-treated mice.
doi:10.1371/journal.pone.0023060.g003
Figure 2. Effects of endogenous PTH deficiency and exogenous PTH on cartilaginous callus formation and on the transformation
into bony callus. Representative micrographs of paraffin sections of calluses from V-WT and V-KO mice, and PTH-WT and PTH-KO mice at (A) 1 week
and (B) 2 weeks post-fracture. Areas of the total callus (C, F), cartilaginous callus (D, G) and bony callus (E, H) were measured by computer-assisted
image analysis. The percentage of increased or reduced (I) total callus, (J) cartilaginous callus and bony callus (K) in response to PTH at 1 and 2 weeks
post-fracture in wild type (WT) and Pth
2/2 (KO) mice. Each value is the mean 6 SEM of determinations in 6 animals from each group. *, P,0.05;
**, P,0.01; ***, P,0.001 compared with WT mice at the same group. #,P ,0.05; ##,P ,0.01; ###,P ,0.001 compared with genotype-matched
V-treated mice.
doi:10.1371/journal.pone.0023060.g002
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progenitor cells, synthesis of bone matrix proteins, and osteoclas-
togenesis, thereby enhancing both callus formation and callus
remodeling. The resulting bones after 4 weeks of treatment with
PTH showed better mechanical strength than fractured bones of
wild type mice treated with vehicle only.
We also found that the administration of exogenous PTH1-34
rescued impaired fracture healing in mice deficient in endogenous
PTH. Interestingly the percent increase in total callous and in
bony callous and in indices of bone formation were generally
higher in the PTH1-34-treated Pth
2/2 mice than in the PTH1-34-
treated wild type mice. Increases in renal phosphaturic and cyclic
AMP responses to exogenous PTH have previously been reported
in hypoparathyroid patients [24]; the apparent increased respon-
siveness to exogenous PTH1-34 in fracture healing may therefore
be evidence of similar enhanced sensitivity in bone. Whether this
apparent relative increase in responsiveness is secondary to
upregulation of PTHR1 in the absence of PTH ligand in
hypoparathyroidism or to some other mechanism will require
further study. Nevertheless despite these relative increases, using
Figure 4. Effects of endogenous PTH deficiency and exogenous PTH on osteoblastic bone formation in calluses at 4 weeks post-
fracture. Representative micrographs of paraffin sections of calluses from V-WT and V-KO mice and PTH-WT and PTH-KO mice at 4 weeks post-
fracture stained with (A) Sirius Red for total collagen, (B) hematoxylin and eosin (HE), (C) histochemically for ALP and (D) immunohistochemically for
type I collagen (Col I). (E) Total collagen positive bony callus areas, (F) osteoblast number relative to bone perimeter (N.Ob/B.Pm, #/mm), (G) ALP
positive areas and (H) Col I immunopositive areas were measured by computer-assisted image analysis. Each value is the mean 6 SEM of
determinations in 6 animals from each group. **, P,0.01; ***, P,0.001 compared with WT mice of the same group. #,P ,0.05; ##,P ,0.01;
###,P ,0.001 compared with genotype-matched V-treated mice.
doi:10.1371/journal.pone.0023060.g004
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callous and bony callous were highest in the PTH-treated wild
type mice which produce endogenous PTH, and this higher
volume of bony callous was associated with bones exhibiting the
most favorable mechanical properties.
Intermittent administration of PTH1-34 or PTH 1-84 has an
‘‘anabolic’’ effect on bone although primarily on trabecular bone
and not cortical bone. Although endogenous PTH under
physiologic conditions is presumably secreted relatively continu-
ously we have previously shown it to be essential for trabecular
bone formation in the fetus and neonate [1,2]. Secondary
hyperparathyroidism, where continuous PTH secretion does
occur, is also associated with increased osteoblast activity and
increased bone matrix production [3]. Primary hyperparathyroid-
ism and continuous administration of exogenous PTH, whether 1–
84 or its active fragment 1–34, are known to produce bone
resorption although primarily in cortical bone rather than in
trabecular bone [25,26,27]. Consequently, just as either contin-
uous or intermittent endogenous or exogenous PTH may have
positive effects on trabecular bone, our data suggest that either
continuous PTH1-84 or intermittent PTH1-34 can have positive
effects on endochondral bone formation during fracture healing.
Overall therefore our studies demonstrate the important role
that endogenous PTH plays in fracture healing and show that
exogenous PTH is more efficacious in increasing callus areas,
endochondral bone formation and callus remodeling and in
producing a bone of greater mechanical strength, in the presence
than in the absence of endogenous PTH.
Author Contributions
Conceived and designed the experiments: DSM. Performed the experi-
ments: YXR BL YXF LS. Analyzed the data: DSM YXR BL XJC.
Contributed reagents/materials/analysis tools: AK DG. Wrote the paper:
DSM YXR.
References
1. Miao D, He B, Karaplis AC, Goltzman D (2002) Parathyroid hormone is
essential for normal fetal bone formation. J Clin Invest 109: 1173–1182.
2. Xue Y, Karaplis AC, Hendy GN, Goltzman D, Miao D (2005) Genetic models
show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and
synergistic roles in postnatal mineral ion homeostasis and skeletal development.
Hum Mol Genet 14: 1515–1528.
3. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, et al. (2001) Targeted
ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for
skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 98:
7498–7503.
4. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, et al. (2007)
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture
and bone mineral density in postmenopausal women with osteoporosis: a
randomized trial. Ann Intern Med 146: 326–339.
5. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, et al. (2003)
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone
Figure 5. Effects of endogenous PTH deficiency and exogenous PTH on osteoclastic bone resorbtion in calluses at 2 and 4 weeks
post-fracture. Representative micrographs of sections of calluses from V-WT and V-KO mice and PTH-WT and PTH-KO mice at (A) 2 weeks and (B) 4
weeks post-fracture stained histochemically for TRAP. (C, D) Number of TRAP-positive osteoclasts related to tissue area (N.Oc/T.Ar, #/mm2) and (E, F)
osteoclast surface relative to bone surface (Oc.S/BS, %) were assessed by computer-assisted image analysis. Each value is the mean 6 SEM of
determinations in 6 animals from each group. *, P,0.05; **, P,0.01 compared with WT mice of the same group. #,P ,0.05; ##,P ,0.01;
###,P ,0.001 compared with genotype-matched V-treated mice.
doi:10.1371/journal.pone.0023060.g005
PTH Accelerates Fracture Healing
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e23060mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:
5212–5220.
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. (2001) Effect
of parathyroid hormone (1-34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
7. Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, et al. (2005)
Enhancement of experimental fracture-healing by systemic administration of
recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am
87: 731–741.
8. Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid
hormone (1-34) treatment increases callus formation and mechanical strength
of healing rat fractures. J Bone Miner Res 14: 960–968.
9. Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA (1999) Parathyroid
hormone enhances fracture healing. A preliminary report. Clin Orthop Relat
Res. pp 258–263.
10. Kim HW, Jahng JS (1999) Effect of intermittent administration of parathyroid
hormone on fracture healing in ovariectomized rats. Iowa Orthop J 19: 71–77.
11. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, et al. (2002)
Mechanisms for the enhancement of fracture healing in rats treated with
intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:
2038–2047.
12. Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid
hormone on fracture healing in ovariectomized rats. Orthopedics 23:
1089–1094.
13. Miao D, He B, Lanske B, Bai XY, Tong XK, et al. (2004) Skeletal abnormalities
in Pth-null mice are influenced by dietary calcium. Endocrinology 145:
2046–2053.
14. Schmidmaier G, Wildemann B, Melis B, Krummrey G, Einhorn TA, et al.
(2004) Development and characterization of a standard closed tibial fracture
model in the rat. European Journal of Trauma 30: 35–42.
15. Liu H, Guo J, Wang L, Chen N, Karaplis A, et al. (2009) Distinctive anabolic
roles of 1,25-dihydroxyvitamin D(3) and parathyroid hormone in teeth and
mandible versus long bones. J Endocrinol 203: 203–213.
16. Sun W, Liu J, Zhou X, Xiao Y, Karaplis A, et al. (2010) Alterations in
phosphorus, calcium and PTHrP contribute to defects in dental and dental
alveolar bone formation in calcium-sensing receptor-deficient mice. Develop-
ment 137: 985–992.
17. Miao D, Bai X, Panda D, McKee M, Karaplis A, et al. (2001) Osteomalacia in
hyp mice is associated with abnormal phex expression and with altered bone
matrix protein expression and deposition. Endocrinology 142: 926–939.
18. Panda DK, Miao D, Bolivar I, Li J, Huo R, et al. (2004) Inactivation of the 25-
hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates
independent and interdependent effects of calcium and vitamin D on skeletal
and mineral homeostasis. J Biol Chem 279: 16754–16766.
19. Miao D, Scutt A (2002) Histochemical localization of alkaline phosphatase
activity in decalcified bone and cartilage. J Histochem Cytochem 50: 333–340.
20. Miao D, Scutt A (2002) Recruitment, augmentation and apoptosis of rat
osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-
dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord 3: 16.
21. Fukuhara H, Mizuno K (1989) [The influence of parathyroid hormone on the
process of fracture healing]. Nippon Seikeigeka Gakkai Zasshi 63: 100–115.
22. Nakazawa T, Nakajima A, Shiomi K, Moriya H, Einhorn TA, et al. (2005)
Effects of low-dose, intermittent treatment with recombinant human parathyroid
hormone (1-34) on chondrogenesis in a model of experimental fracture healing.
Bone 37: 711–719.
23. Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, et al. (2007) Enhanced
chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res
22: 1903–1912.
24. Law WM, Jr., Heath H, III (1984) Increased renal responses to exogenous
parathyroid hormone in postsurgical hypoparathyroidism. J Clin Endocrinol
Metab 59: 394–397.
25. Parisien M, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, et al. (1990) The
histomorphometry of bone in primary hyperparathyroidism: preservation of
cancellous bone structure. J Clin Endocrinol Metab 70: 930–938.
26. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, et al. (1989)
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4: 283–291.
27. Zhou H, Shen V, Dempster DW, Lindsay R (2001) Continuous parathyroid
hormone and estrogen administration increases vertebral cancellous bone
volume and cortical width in the estrogen-deficient rat. J Bone Miner Res 16:
1300–1307.
PTH Accelerates Fracture Healing
PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e23060